273 related articles for article (PubMed ID: 19398704)
1. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles.
Bennett DA; De Jager PL; Leurgans SE; Schneider JA
Neurology; 2009 Apr; 72(17):1495-503. PubMed ID: 19398704
[TBL] [Abstract][Full Text] [Related]
2. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model.
Martins CA; Oulhaj A; de Jager CA; Williams JH
Neurology; 2005 Dec; 65(12):1888-93. PubMed ID: 16380608
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.
Bennett DA; Wilson RS; Schneider JA; Evans DA; Aggarwal NT; Arnold SE; Cochran EJ; Berry-Kravis E; Bienias JL
Neurology; 2003 Jan; 60(2):246-52. PubMed ID: 12552039
[TBL] [Abstract][Full Text] [Related]
4. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
[TBL] [Abstract][Full Text] [Related]
5. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease.
Tiraboschi P; Hansen LA; Masliah E; Alford M; Thal LJ; Corey-Bloom J
Neurology; 2004 Jun; 62(11):1977-83. PubMed ID: 15184600
[TBL] [Abstract][Full Text] [Related]
6. APOE ε4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death.
Yu L; Boyle P; Schneider JA; Segawa E; Wilson RS; Leurgans S; Bennett DA
Psychol Aging; 2013 Dec; 28(4):1015-23. PubMed ID: 23647000
[TBL] [Abstract][Full Text] [Related]
7. The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series.
Tsuang D; Larson EB; Bowen J; McCormick W; Teri L; Nochlin D; Leverenz JB; Peskind ER; Lim A; Raskind MA; Thompson ML; Mirra SS; Gearing M; Schellenberg GD; Kukull W
Arch Neurol; 1999 Dec; 56(12):1489-95. PubMed ID: 10593304
[TBL] [Abstract][Full Text] [Related]
8. The effect of APOE genotype on clinical phenotype in Alzheimer disease.
Borroni B; Di Luca M; Padovani A
Neurology; 2007 Feb; 68(8):624; author reply 624. PubMed ID: 17310043
[No Abstract] [Full Text] [Related]
9. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep.
Lim AS; Yu L; Kowgier M; Schneider JA; Buchman AS; Bennett DA
JAMA Neurol; 2013 Dec; 70(12):1544-51. PubMed ID: 24145819
[TBL] [Abstract][Full Text] [Related]
10. APOE, vascular pathology, and the AD brain.
Yip AG; McKee AC; Green RC; Wells J; Young H; Cupples LA; Farrer LA
Neurology; 2005 Jul; 65(2):259-65. PubMed ID: 16043796
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.
Premkumar DR; Cohen DL; Hedera P; Friedland RP; Kalaria RN
Am J Pathol; 1996 Jun; 148(6):2083-95. PubMed ID: 8669492
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.
Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV
Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211
[TBL] [Abstract][Full Text] [Related]
13. Association of Uncommon, Noncoding Variants in the APOE Region With Risk of Alzheimer Disease in Adults of European Ancestry.
Blue EE; Cheng A; Chen S; Yu CE;
JAMA Netw Open; 2020 Oct; 3(10):e2017666. PubMed ID: 33090224
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.
Hsiung GY; Sadovnick AD; Feldman H
CMAJ; 2004 Oct; 171(8):863-7. PubMed ID: 15477624
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E epsilon4 allele frequency in elderly depressed patients with and without cerebrovascular disease.
Traykov L; Bayle AC; Latour F; Lenoir H; Seux ML; Hanon O; Péquignot R; Bert P; Moulin F; Cantegreil I; Wenisch E; Batouche F; Mehrabian S; Rotrou Jd; Rigaud AS
J Neurol Sci; 2007 Jun; 257(1-2):280-3. PubMed ID: 17337010
[TBL] [Abstract][Full Text] [Related]
16. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease.
Cosentino S; Scarmeas N; Helzner E; Glymour MM; Brandt J; Albert M; Blacker D; Stern Y
Neurology; 2008 May; 70(19 Pt 2):1842-9. PubMed ID: 18401023
[TBL] [Abstract][Full Text] [Related]
17. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
18. Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease.
Yu L; Petyuk VA; Tasaki S; Boyle PA; Gaiteri C; Schneider JA; De Jager PL; Bennett DA
JAMA Neurol; 2019 Jul; 76(7):818-826. PubMed ID: 31009033
[TBL] [Abstract][Full Text] [Related]
19. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
Klages JD; Fisk JD; Rockwood K
Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
[TBL] [Abstract][Full Text] [Related]
20. Association of APOE with tau-tangle pathology with and without β-amyloid.
Farfel JM; Yu L; De Jager PL; Schneider JA; Bennett DA
Neurobiol Aging; 2016 Jan; 37():19-25. PubMed ID: 26481403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
